Harvard Bioscience, Inc. (HBIO) Earnings Call Analysis
NASDAQ · Healthcare · Medical Instruments & Supplies
Earnings Reports
-
Harvard Bioscience (HBIO) Q1 2026: NPI Revenue Rises to 20%, Margin Path Clears for 60%+
June 17, 2026
-
Harvard Bioscience (HBIO) Q4 2025: Gross Margin Expands 260bps as Product Mix and Cost Actions Reshape Core
June 17, 2026
-
Harvard Bioscience (HBIO) Q2 2025: Cash Flow Jumps to $2.8M as Cost Actions Offset Revenue Dip
June 16, 2026
-
Harvard Bioscience (HBIO) Q3 2025: Backlog Hits Two-Year High as Margin Expands 200bps
June 16, 2026
-
Harvard Bioscience (HBIO) Q4 2025: Gross Margin Hits 60% as Platform Shift Accelerates Recurring Revenue
June 15, 2026